An observational study in Prostate Cancer, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to male participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Prostatic Neoplasms by IRCCS San Raffaele — 7 open to participants now, 9 under way, none of them phase 3. Prostatic Neoplasms · IRCCS San Raffaele.
Among the 28 studies in Prostatic Neoplasms by IRCCS San Raffaele, this one is the 2nd largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2022, is one of 18 observational ones, and was the 24th registered.
7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →7 of the 28 studies in Prostatic Neoplasms by IRCCS San Raffaele are open now, in 1 country. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Men only
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Men only
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Men only
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Men only
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 95 Years · male.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 76 across the 10 interventional studies, 251 across the 18 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
2 of the studies in Prostatic Neoplasms by IRCCS San Raffaele that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06546267IRCCS San RaffaeleAdvanced Radiotherapy (ART) in Prostate Cancer (PROST-ART) | 2027-02-14 |
| NCT06167629IRCCS San RaffaeleMonocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer | 2027-07-13 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Prostatic Neoplasms by IRCCS San Raffaele, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (IGRT, IMRT, SBRT, and PET-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high, and very high-risk prostate cancer, or with biochemical, lymph node, or oligometastatic recurrence treated between 2004 and 2024.
Approved by Ethics Committee of IRCCS San Raffaele Hospital Approval Number: 187/INT/2021, 03/02/2022
Amendment approved by Ethics Committee 1, Lombardy Region Approval number CET Em. 194-2024, 22/05/2024
This is a single-center, retrospective study (PROST-ART) that has as its primary objective the evaluation of the efficacy of radiotherapy treatments performed in patients with early-stage, advanced, metastatic prostate disease, with biochemical relapses after surgery, with local relapses after radiotherapy, or oligometastatic/oligoprogressive disease. The aim of the study is to measure the biochemical relapse-free survival (bRFS), local and regional relapse (LR, regional relapse, RR), distant metastases-free survival (DMS), clinical relapse (DFS), disease-free survival (PCSS), and overall survival (OS) from both disease diagnosis and the end of radiotherapy until the last useful follow-up, or until the patient's death. In addition, the acute and late toxicity of treatments will be assessed from the start of treatment until the last follow-up/death of the patient and the period without other oncological treatments, from the end of treatment until the start of another oncological treatment/last follow-up.
At least 200 patients treated in the last 5 years, some receiving stereotactic radiotherapy to the prostate, or prostate and seminal vesicles, and the others pelvic lymph node and prostate irradiation, who are still alive and contactable, and agree to participate, will be included in a survey on quality of life (QoL). These patients, after signing an informed consent for the collection of new information, will receive an EORTC QLQ-PR25 quality of life questionnaire, in order to quantify the impact of toxicity. In addition, the radiomic characteristics of the computed tomography/ PET-CT performed for treatment planning along with evaluation of the results will be extracted to identify related predictive factors.
The QoL study is configured as retrospective as the questionnaire will only be an expression, from the patient's point of view, of the toxicity of the previous treatment.
Prostate cancer patients with early-stage, advanced, metastatic prostate disease, with biochemical relapses after surgery, with local relapses after radiotherapy, or oligometastatic/oligoprogressive disease (lymph nodes, bone, visceral)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients treated with IGRT, IMRT, SBRT, with radical intent for localized prostate cancer will be evaluated Other Names: Intensity Modulated Radiotherapy Stereotactic Body Radiotherapy
Radiation: Image Guided Radiotherapy · Radiation: Intensity Modulated Radiotherapy · Radiation: Stereotactic Body Radiotherapy
Patients operated on for prostate cancer, treated with IGRT, IMRT, SBRT in adjuvant setting will be evaluated Other Names: Intensity Modulated Radiotherapy Stereotactic Body Radiotherapy
Radiation: Image Guided Radiotherapy · Radiation: Intensity Modulated Radiotherapy · Radiation: Stereotactic Body Radiotherapy
Patients operated on for prostate cancer and treated with IGRT, IMRT, SBRT for biochemical relapse will be evaluated
Radiation: Image Guided Radiotherapy · Radiation: Intensity Modulated Radiotherapy · Radiation: Stereotactic Body Radiotherapy
Prostate cancer patients treated with IGRT, IMRT, SBRT, in radical setting or as salvage radiotherapy for relapse after previous treatments will be evaluated
Radiation: Image Guided Radiotherapy · Radiation: Intensity Modulated Radiotherapy · Radiation: Stereotactic Body Radiotherapy
Patients treated with IGRT for Prostate cancer will be evaluated
Also known as: IGRT
Patients treated with IMRT for Prostate cancer will be evaluated
Also known as: IMRT
Patients treated with SBRT for Prostate cancer will be evaluated
Also known as: SBRT, SRT, SABR (Stereotactic Ablative Radiotherapy)
Local Relapse Free Survival
Local control of the disease (at the treated site)
Time frame: From the date of radiotherapy end until the date of local progression or date of death from any cause, whichever came first, assessed up to 120 months
Regional Relapse Free Survival
Regional control of the disease (at the regional lymph node chain)
Time frame: From the date of radiotherapy end until the date of regional progression or date of death from any cause, whichever came first, assessed up to 120 months
Distant Metastasis Free Survival
Distant Metastasis developed after the treatment
Time frame: From the date of radiotherapy end until the date of distant progression or date of death from any cause, whichever came first, assessed up to 120 months
Biochemical relapse free survival
Biochemical relapse after the treatment
Time frame: From the date of radiotherapy end until the date of biochemical progression or date of death from any cause, whichever came first, assessed up to 120 months
Disease Free Survival
Absence of disease progression during the follow-up
Time frame: From the date of radiotherapy end until the date of first documented clinical progression or date of death from any cause, whichever came first, assessed up to 120 months
Overall Survival
Survival from all causes
Time frame: From the date of radiotherapy end until the date of death from any cause, assessed up to 120 months
Cancer Specific Survival
Cancer Survival
Time frame: From the date of radiotherapy end until the date of death from disease progression, assessed up to 120 months
Acute Toxicity
Toxicity developed in the first three months after the treatment, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which displayes grades from 1 to 5, with grade 1 meaning mild toxicity and grade 5 death related to toxicity
Time frame: Up to three months from the start of radiotherapy
Late toxicity
Toxicity developed after three months until the end of follow-up or death, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which displayes grades from 1 to 5, with grade 1 meaning mild toxicity and grade 5 death related to toxicity
Time frame: From three months after the start of radiotherapy until the end of follow-up or death, assessed up to 120 months
Predictive factors for disease progression and death
Factors predicting survival. Survival trees, univariate/multivariate Cox regression models will be estimated to identify potential risk factors associated with survival outcomes
Time frame: From radiotherapy end to date of local, regional progression, distant failure, or death, assessed up to 120 months
Radiomic predictive factors for disease progression and death
CT and PET/CT radiomic features predicting relapse or death will be extracted, acording to IBSI (Image Biomarker Standardisation Initiative), owning to the different families of features: Morphology, Statistical, Intensity Histogram, Grey Level Cooccurrence Matrix 3D-average, Grey Level Co-occurrence Matrix 3D-combined, Grey Level Run Lenght 3D-average. Grey Level Run Lenght 3D\_combined, Grey Level Size Zone Matrix 3D, Neighbors Grey Tone Difference Matrix 3D, Grey Level Distance Zone Matrix 3D, standard convolutional filters within radiomic workflow (wavelets, Laplacian of Gaussian)
Time frame: From radiotherapy end to the first registered event (disease progression or death), assessed up to 120 months
Plan to share: Yes — The data that support the findings of this study (anonymized individual participant data) are available on request from the corresponding author to researchers who provide a methodologically sound proposal. Requests made to the corresponding author (AF) will be evaluated by the Lombardy Territorial Ethics Committee 1.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: for another 2 years after the closure of the study
Access criteria: Request from the corresponding author approved by the Lombardy Territorial Ethics Committee 1
Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Feb 2027, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.